Welcome to our dedicated page for LXXGF news (Ticker: LXXGF), a resource for investors and traders seeking the latest updates and insights on LXXGF stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect LXXGF's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of LXXGF's position in the market.
LexaGene Holdings (OTCQB: LXXGF) announced that its MiQLab® System can perform the CDC Monkeypox real-time PCR test. Following the WHO's declaration of Monkeypox as a public health emergency on July 23, 2022, and subsequent U.S. emergency declaration on August 4, the system aims to address potential infection spikes during back-to-school activities. The MiQLab System, designed for rapid pathogen detection, positions LexaGene to pursue FDA EUA once declared, although no claims of curing or containing Monkeypox have been made.
LexaGene Holdings, Inc. (OTCQB: LXXGF) announced it has configured its MiQLab System to utilize isothermal chemistry for individual pathogen detection in as little as 30 minutes. This development complements existing real-time PCR capabilities, enhancing its molecular diagnostics for veterinary use. The system can now identify Leptospira DNA swiftly, crucial for treating leptospirosis in pets. The company is working on further validations before commercial release, which may involve altering time-to-result metrics for various pathogen tests.
LexaGene Holdings (OTCQB: LXXGF) has initiated an evaluation of a gastrointestinal (GI) pathogen panel in collaboration with the University of Pennsylvania’s School of Veterinary Medicine. This GI panel aims to address the diagnostic challenges veterinarians face with acute diarrhea in companion animals. It tests for 5 bacteria, 11 toxin genes, 4 protozoans, and a virus family, enabling rapid identification of pathogens to guide treatment. The MiQLab System, designed for on-site detection, showcases LexaGene's commitment to improving veterinary diagnostics.
LexaGene Holdings, Inc. (OTCQB: LXXGF) announced a significant improvement in the reporting speed of its MiQLab® System for PCR-based veterinary diagnostics. The system's processing time has been reduced from 120 minutes to just 80 minutes, enhancing the efficiency of detecting 10 pathogens and 33 antimicrobial resistance markers. CEO Dr. Jack Regan highlighted the importance of fast results in veterinary care, reinforcing the company's commitment to data integrity. The new improvements are expected to be available to customers in 4-6 weeks following further validation tests.
LexaGene Holdings, Inc. (OTCQB: LXXGF) filed its audited financial statements for the year ended February 28, 2022, and unaudited interim statements for the three months ended May 31, 2022. This led to the revocation of the management cease trade order (MCTO) from the British Columbia Securities Commission. The company granted 1,085,000 stock options and 1,525,000 restricted share units, with stock options exercisable at CAD$0.20. The last trading price was CAD$0.13.
LexaGene Holdings, a molecular diagnostics firm, has released preliminary data from a clinical study conducted at top veterinary universities. The study involved the MiQLab System, which detected 10 pathogens and 33 antimicrobial resistance markers in urine samples. Out of 105 tested specimens, 39 were relevant for urinary tract infections. The MiQLab System showed a sensitivity of 97%, specificity of 91%, and an overall agreement of 93%. CEO Jack Regan emphasized the system’s rapid turnaround time of 2 hours for results, enhancing diagnostic efficiency.
LexaGene Holdings, Inc. (OTCQB: LXXGF) has provided an update on its management cease trade order (MCTO) issued by the British Columbia Securities Commission due to delays in annual financial filings. The Company is making progress with its audit team and expects to file the required documents by August 29, 2022. There are no known material issues affecting the filings, and the company will continue to issue bi-weekly reports during this period. The MCTO affects only the CEO and CFO's trading, while other security holders retain trading capabilities.
LexaGene Holdings, a molecular diagnostics company, announced a webinar on July 26, 2022, titled 'The Wave of the Future: In-Clinic PCR Diagnosis,' presented by UC Davis Professor Dr. Jane Sykes. The webinar aims to address challenges in diagnosing urinary tract infections and the growing threat of antimicrobial resistance. It will discuss the MiQLab System's capabilities for rapid testing of pathogens and antimicrobial resistance factors in veterinary clinics.
LexaGene Holdings, Inc. (OTCQB: LXXGF) has signed a purchase agreement with a Wisconsin veterinary hospital for its MiQLab® System, which automates PCR-based syndromic testing. CEO Dr. Jack Regan highlighted a significant growth of 240% in the company’s install base since the start of the year, expecting further increases. Once installations are complete, MiQLab Systems will be operational in 10 states across the U.S., underscoring the expanding reach and market acceptance of LexaGene's technology.
LexaGene Holdings, Inc. (OTCQB: LXXGF) has been granted a management cease trade order (MCTO) by the authorities due to delays in filing its annual financial statements for the year ending February 28, 2022. The MCTO restricts certain insiders from trading the company's securities until the required filings are submitted by August 29, 2022. The company is in the process of completing the audit necessary for these filings and expects to update stakeholders within five to six weeks. LexaGene assures compliance with alternative information guidelines during this period.
FAQ
What is the market cap of LXXGF (LXXGF)?
